Serafin Morales Murillo

Martín M; Loibl S; von Minckwitz G; Morales S; Martinez N; Guerrero A; Anton A; Aktas B; Schoenegg W; Muñoz M; Garcia-Saenz JÁ; Gil M; Ramos M; Margeli M; Carrasco E; Liedtke C; Wachsmann G; Mehta K; De la Haba-Rodriguez JR

Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study

Journal of Clinical Oncology 33 1045-1045. 20/03/2015.

[doi:10.1200/JCO.2014.57.2388]

Salazar, R.; Morales, S.; Gil-Martín, M.; Aguirre, E.; Oaknin, A.; Garcia, M.; Callies, S.; Wickremsinhe, E.R.; Benhadji, K.A.; Llombart, A.

Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors

CANCER CHEMOTHERAPY AND PHARMACOLOGY 73 1205-1215. 01/06/2014.

[doi:10.1007/s00280-014-2457-1]

Aguirre, E.; Morales, S.; Llombart, A.

Other malignancies I. breast cancer

Other Malignancies I. Breast Cancer 235-251. 01/01/2014.

Sanchez-Rovira, P.; Segui, M. A.; Llombart, A.; Aranda, E.; Anton, A.; Sanchez, A.; Lomas, M.; Jaen, A.; Fernandez, M.; Porras, I.; Dalmau, E.; Morales, S.; de la Haba-Rodriguez, J.

Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response

CLINICAL & TRANSLATIONAL ONCOLOGY 15 810-817. 01/10/2013.

[doi:10.1007/s12094-013-1006-4]

Aguirre E; Taberner T; Luaña A; Morales S; Llombart A

Severe thrombocytopenia related to long-term trastuzumab exposure.

Tumori 99 -. 01/01/2013.

[doi:10.1700/1248.13801]

Martin, Miguel; Segui, Miguel A.; Anton, Antonio; Ruiz, Amparo; Ramos, Manuel; Adrover, Encarna; Aranda, Ignacio; Rodriguez-Lescure, Alvaro; Grosse, Regina; Calvo, Lourdes; Barnadas, Agusti; Isla, Dolores; Martinez del Prado, Purificacion; Ruiz Borrego, Manuel; Zaluski, Jerzy; Arcusa, Angels; Munoz, Montserrat; Lopez Vega, Jose M.; Mel, Jose R.; Munarriz, Blanca; Llorca, Cristina; Jara, Carlos; Alba, Emilio; Florian, Jesus; Li, Junfang; Lopez Garcia-Asenjo, Jose A.; Saez, Amparo; Jose Rios, Maria; Almenar, Sergio; Peiro, Gloria; Lluch, Ana; GEICAM 9805 Investigators

Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer.

NEW ENGLAND JOURNAL OF MEDICINE 363 2200-2210. 02/12/2010.

[doi:10.1056/NEJMoa0910320]

Aguirre Ortega, E.; Martín Marco, A.; Canal Sotelo, J.; Morales Murillo, S.; Llombart Cussac, A.

Dyspnea and persistent cough as first signs of distant recurrence disease

MEDICINA DE FAMILIA-SEMERGEN 36 597-599. 01/01/2010.

[doi:10.1016/j.semerg.2010.02.011]

Rosell, Rafael; Moran, Teresa; Queralt, Cristina; Porta, Rut; Cardenal, Felipe; Camps, Carlos; Majem, Margarita; Lopez-Vivanco, Guillermo; Isla, Dolores; Provencio, Mariano; Insa, Amelia; Massuti, Bartomeu; Luis Gonzalez-Larriba, Jose; Paz-Ares, Luis; Bover, Isabel; Garcia-Campelo, Rosario; Angel Moreno, Miguel; Catot, Silvia; Rolfo, Christian; Reguart, Noemi; Palmero, Ramon; Miguel Sanchez, Jose; Bastus, Roman; Mayo, Clara; Bertran-Alamillo, Jordi; Angel Molina, Miguel; Javier Sanchez, Jose; Taron, Miquel; Spanish Lung Canc Grp

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.

NEW ENGLAND JOURNAL OF MEDICINE 361 958-38. 03/09/2009.

[doi:10.1056/NEJMoa0904554]

Baselga, J; Carbonell, X; Castaneda-Soto, NJ; Clemens, M; Green, M; Harvey, V; Morales, S; Barton, C; Ghahramani, P

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule

Journal of Clinical Oncology 23 2162-2171. 01/04/2005.

[doi:10.1200/JCO.2005.01.014]

Espinosa, E; Morales, S; Borrega, P; Casas, A; Madronal, C; Machengs, I; Illarramendi, J; Lizon, J; Moreno, J; Belon, J; Janariz, J; de la Puente, M; Checa, T; Mel, JR; Baron, MG

Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer

CANCER CHEMOTHERAPY AND PHARMACOLOGY 54 546-552. 01/12/2004.

[doi:10.1007/s00280-004-0830-1]

Morales, S; Lorenzo, A; Ramos, M; Ballesteros, P; Mendez, M; Almanza, C; Castellanos, J; Moreno-Nogueira, JA; Casal, J; Lizon, J; Oltra, A; Frau, A; Machengs, I; Galan, A; Belon, J; Llorca, C

Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study

CANCER CHEMOTHERAPY AND PHARMACOLOGY 53 75-81. 01/01/2004.

[doi:10.1007/s00280-003-0690-0]

Alberola, V; Camps, C; Provencio, M; Isla, D; Rosell, R; Vadell, C; Bover, I; Ruiz-Casado, A; Azagra, P; Jimenez, U; Gonzalez-Larriba, JL; Diz, P; Cardenal, F; Artal, A; Carrato, A; Morales, S; Sanchez, JJ; de las Penas, R; Felip, E; Lopez-Vivanco, G

Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish lung cancer group phase III randomized trial

Journal of Clinical Oncology 21 3207-3213. 01/09/2003.

[doi:10.1200/JCO.2003.12.038]